Tag Archives: Wyeth

AstraZeneca, BMS Announce Layoffs and Buyouts

By George Koroneos | Published: October 21, 2009
AstraZeneca was the topic of conversation this week as word broke that the company is offering buyout deals to every member of its 5,500 US sales force. “AstraZeneca is making changes to our sales force, which will be managed first by looking at vacancies and offering field sales employees the opportunity to self-identify whether they are [...]
Posted in Strategy | Also tagged , , , , , , , | 1 Comment

Avastin Gets Green Light for Use in Kidney Cancer

By George Koroneos | Published: August 5, 2009
Image by Getty Images via Daylife Score another win for Genentech and its cancer treatment Avastin (bevacizumab). On Monday, the biotech giant, now owned entirely by Roche, announced that FDA has approved the drug for kidney cancer. Avastin blocks new blood vessels from forming and supplying tumors with the nutrients they need to grow and spread to [...]
Posted in News | Also tagged , , , , , , | Leave a comment

March Issue of Pharm Exec Online Now

By George Koroneos | Published: March 13, 2009
The March issue of Pharmaceutical Executive Magazine is online and in the mail as we speak. The new issue features insights into the Pfizer/Wyeth merger, our annual media audit, a look at the new sales force model, and the 2009 Ad Stars. Click here to check it out. The March issues also comes with the [...]
Posted in Pharm Exec Magazine | Also tagged , , , , , | Leave a comment

Pfizer to Buy Wyeth for $68 Billion

By George Koroneos | Published: January 26, 2009
Pfizer made it official this morning. The pharma giant acquired Wyeth for $50.19 a share or $68 billion in cash and stocks, and news of the merger sent ripples through the pharma industry: Pfizer Broadens Beyond Pills with $68 Billion Wyeth Buy: Pfizer has agreed to acquire Wyeth in a $68 billion deal that’s the largest [...]
Posted in Deals | Also tagged , , , | Leave a comment